How India Exports Lorazepam to the World

Lorazepam, a benzodiazepine used primarily for anxiety disorders, has been available in the U.S. market for several decades. The FDA approved the first generic versions of lorazepam in the late 1990s. For instance, Elkins-Sinn received approval for their generic lorazepam on September 28, 1998, and Mova Pharmaceutical Corporation's lorazepam injection was approved on March 16, 2000.

The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for lorazepam, indicating a competitive generic market. As of March 2026, there are no active import alerts or significant regulatory actions against lorazepam products from India. This regulatory stability aligns with our data, which shows that 24 Indian exporters have successfully shipped lorazepam to the U.S., accounting for 45.6% of the total export value.

In the European Union, lorazepam is subject to stringent regulatory oversight. The European Medicines Agency (EMA) has evaluated lorazepam-containing products, such as Lorazepam Macure. In June 2024, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended updating the product information to include the control of status epilepticus in various age groups. However, they also highlighted potential risks associated with excipients in young children (ema.europa.eu).

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) continues to align with EMA guidelines post-Brexit, ensuring that lorazepam products meet EU Good Manufacturing Practice (GMP) standards. Our data indicates that the UK is a significant importer, accounting for 13.4% of India's lorazepam exports.

Lorazepam is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global healthcare. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality across different markets.

In India, lorazepam is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on lorazepam, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for controlled substances, ensuring compliance with international regulations.

The primary patents for lorazepam have long expired, leading to a robust generic market. This has facilitated the entry of multiple Indian manufacturers into the global market, as evidenced by our data showing 24 active exporters.

In June 2024, the EMA recommended updating the product information for Lorazepam Macure to include the treatment of status epilepticus and highlighted potential risks associated with certain excipients in young children (ema.europa.eu).

In August 2024, the European Commission issued a legally binding decision to implement these changes across EU member states (ema.europa.eu).

In January 2025, the NPPA conducted a review of benzodiazepine pricing, including lorazepam, but decided against imposing a ceiling price, maintaining a market-driven approach.

In March 2025, the FDA approved a new generic version of lorazepam oral concentrate, further increasing competition in the U.S. market.

In October 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of lorazepam for the management of anxiety and seizure disorders.

Lorazepam, a benzodiazepine used for anxiety and seizure disorders, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the pharmaceutical raw material market.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, the closure of the Strait of Hormuz disrupted the supply of naphtha, a critical feedstock for chemical production, affecting Asian chemical manufacturers. Facilities that rely on Middle Eastern naphtha began experiencing procurement delays, leading to force majeure declarations and production cutbacks. Such disruptions highlight the fragility of supply chains dependent on specific regions for essential raw materials.

Our proprietary trade data indicates that the top five Indian exporters of Lorazepam account for 79.6% of total exports, with APL Healthcare Limited alone contributing 37.7%. This high supplier concentration poses a significant risk; any operational or compliance issues within these key companies could disrupt the global supply of Lorazepam.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to reduce import dependence on critical pharmaceutical ingredients. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, which had not been produced domestically for over two decades. While this initiative is a positive step, its immediate impact on Lorazepam's supply chain remains limited, necessitating further diversification efforts.

The closure of the Strait of Hormuz in February 2026, following US-Israeli airstrikes on Iran, led to a complete halt of commercial shipping through this critical passage. This disruption affected approximately 20% of the world's daily oil supply and significant volumes of liquefied natural gas, causing oil prices to surge and leading major shipping firms to suspend operations in the area. Consequently, Europe-bound shipments from India became costlier and slower, as vessels were forced to reroute around the Cape of Good Hope, extending transit times by 10–20 days and raising freight rates by 40–50%.

Additionally, the Red Sea has experienced heightened security risks, prompting major carriers to suspend or restrict transits. On March 2, 2026, the Joint Maritime Information Center assessed the regional maritime threat as critical, following multiple attacks on merchant vessels within 24 hours. These geopolitical tensions and shipping disruptions have significantly impacted the global pharmaceutical supply chain, including the export of Lorazepam from India.

• Diversify API and KSM Sources: Encourage Indian manufacturers to source KSMs from multiple countries to reduce dependency on China.

• Enhance Domestic Production: Invest in domestic production facilities for critical KSMs and APIs to strengthen supply chain resilience.

• Strengthen Supplier Networks: Develop relationships with a broader range of suppliers to mitigate risks associated with high supplier concentration.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains.

• Develop Contingency Plans: Create and regularly update contingency plans to address potential disruptions in shipping routes and raw material supplies.

RISK_LEVEL: HIGH